Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...

A research team describes how they engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, ...

A research team has found that compounds in the nucleic acids derived from food can inhibit the growth of certain cancer cells. When people eat, they ingest the nucleic acids that reside in all living ...